A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: Proof of principle with rituximab and ofatumumab

Journal of Immunological Methods

Volumn 388, Issue 1-2, 2013, Pages 8-17

  Engelberts, Patrick J ^a   Badoil, Carole ^b   Beurskens, Frank J ^a   Boulay Moine, Danièle ^b   Grivel, Karine ^b   Parren, Paul W H I ^a   Moulard, Maxime ^b  

^a GENMAB   (Netherlands)

^b Biocytex   (France)

Author keywords

ABC; Kinetics; Ofatumumab; Quantitative flow cytometry; Rituximab

Indexed keywords

CD20 ANTIBODY; CHIMERIC ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2H11; MONOCLONAL ANTIBODY 2H12; MONOCLONAL ANTIBODY 4H10; MONOCLONAL ANTIBODY B9E9; MONOCLONAL ANTIBODY HUIGG1 7D8; MONOCLONAL ANTIBODY J4.119; MONOCLONAL ANTIBODY MUIGG1 7D8; MONOCLONAL ANTIBODY MUIGG2A 7D8; OFATUMUMAB; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIBODY COMBINING SITE; ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; BINDING KINETICS; BLOOD; CALIBRATOR; CELL SURFACE; CONTROLLED STUDY; DISSOCIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; BINDING SITES, ANTIBODY; BLOOD; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; KINETICS;

EID: 84872618675     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.11.007     Document Type: Article

References (35)

1. Beers S.A., et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010, 115(25):5191-5201.
2. Beum P.V., et al. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J. Immunol. 2006, 176(4):2600.
3. Beum P.V., Lindorfer M.A., Taylor R.P. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J. Immunol. 2008, 181(4):2916.
4. Beurskens F.J., et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J. Immunol. 2012, 188(7):3532.
5. Bil J., et al. Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity. Blood 2010, 115(18):3745.
6. Bleeker W.K., et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br. J. Haematol. 2008, 140(3):303.
7. Boross P., et al. Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice. Immunol. Lett. 2012, 143(1):44.
8. Czuczman M.S., et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin. Cancer Res. 2008, 14(5):1561.
9. D'Arena G., et al. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am. J. Hematol. 2000, 64(4):275.
10. Davis K.A., et al. Determination of CD4 antigen density on cells: role of antibody valency, avidity, clones, and conjugation. Cytometry 1998, 33(2):197.
11. Ginaldi L., et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J. Clin. Pathol. 1998, 51(5):364.
12. Henderson L.O., et al. Terminology and nomenclature for standardization in quantitative fluorescence cytometry. Cytometry 1998, 33(2):97.
13. Hiraga J., et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009, 113(20):4885.
14. Huh Y.O., et al. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am. J. Clin. Pathol. 2001, 116(3):437.
15. Hulkkonen J., et al. Surface antigen expression in chronic lymphocytic leukemia: clustering analysis, interrelationships and effects of chromosomal abnormalities. Leukemia 2002, 16(2):178.
16. Jasper G.A., et al. Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry B Clin. Cytom. 2011, 80(2):83.
17. Lammerts van Bueren J.J., et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res. 2006, 66(15):7630.
18. Leget G.A., Czuczman M.S. Use of rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. 1998, 10(6):548.
19. Li B., et al. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 2009, 114(24):5007.
20. Marti G.E., Gaigalas A., Vogt R.F. Recent developments in quantitative fluorescence calibration for analyzing cells and microarrays. Cytometry 2000, 42(5):263.
21. Mossner E., et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010, 115(22):4393.
22. Niederfellner G., et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011, 118(2):358.
23. Olejniczak S.H., et al. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol. Invest. 2006, 35(1):93.
24. Reff M.E., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83(2):435.
25. Schwartz A., et al. Standardizing flow cytometry: construction of a standardized fluorescence calibration plot using matching spectral calibrators. Cytometry 1996, 26(1):22.
26. Serke S., van Lessen A., Huhn D. Quantitative fluorescence flow cytometry: a comparison of the three techniques for direct and indirect immunofluorescence. Cytometry 1998, 33(2):179.
27. Tam C.S., et al. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br. J. Haematol. 2008, 141(1):36.
28. Teeling J.L., et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004, 104(6):1793.
29. Teeling J.L., et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 2006, 177(1):362.
30. van Meerten T., et al. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin. Cancer Res. 2006, 12(13):4027.
31. van Meerten T., et al. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis. Haematologica 2010, 95(12):2063.
32. Wierda W.G., et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2010, 28(10):1749.
33. Williams M.E., et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J. Immunol. 2006, 177(10):7435.
34. Winiarska M., et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med. 2008, 5(3):e64.
35. Zenger V.E., et al. Quantitative flow cytometry: inter-laboratory variation. Cytometry 1998, 33(2):138.